The Quiet Battle Defining a $10 Billion Industry
Psychedelic therapy is not just being approved. It is being defined.
Behind the headlines of regulatory breakthroughs and clinical milestones, a far more consequential battle is unfolding, one that will determine not just how psychedelic therapy is delivered, but who controls its future.
This is the Protocol Wars.
At stake is a deceptively simple question: What does “correct” psychedelic therapy actually look like?
The answer is anything but simple.
Across boardrooms, clinical trial sites, underground circles, and indigenous communities, competing visions are emerging. Each claims legitimacy. Each claims efficacy. And increasingly, each is incompatible with the others.
On one side, pharmaceutical backed models push for standardisation, replicability, and regulatory compliance. On another, therapists advocate for adaptive, patient led approaches grounded in relational care. Meanwhile, traditional practitioners argue that modern systems are stripping psychedelics of their cultural and spiritual integrity.
Overlay all of this with investor pressure, clinic scalability demands, and regulatory caution, and the result is a fragmented ecosystem heading toward collision.
The Protocol Wars are not theoretical. They are happening now.
The Rise of the Clinical Protocol
To understand the current landscape, it helps to look at the dominant force shaping psychedelic therapy today: the clinical protocol.
Organisations like MAPS have spent decades developing structured, manualised approaches to psychedelic-assisted therapy, particularly with MDMA.
These protocols are designed to satisfy regulators such as the FDA, where consistency is everything. Every variable must be controlled. Every session must be reproducible. Every outcome must be measurable.
This has led to highly specific therapeutic frameworks:
- Predefined preparation sessions
- Fixed dosing schedules
- Controlled environments
- Two-therapist models
- Integration protocols post-session
From a regulatory perspective, this is essential. Without standardisation, approval pathways collapse.
But something is lost in translation.
Psychedelic experiences are inherently unpredictable. They are shaped by psychology, environment, intention, and relationship variables that resist rigid control. Attempting to force them into standardised frameworks introduces a fundamental tension, can something so subjective be meaningfully standardised without diminishing its effectiveness?
That question sits at the heart of the Protocol Wars.
When Approval Becomes Constraint
The recent rejection of MDMA assisted therapy by the U.S. Food and Drug Administration sent shockwaves through the industry.
For many, it exposed a deeper issue: regulatory frameworks may not be equipped to evaluate therapies that are experiential rather than purely pharmacological.
Clinical trials demand clean data. Psychedelic therapy produces messy, deeply personal outcomes that do not always fit neatly into standard metrics.
Critics argue that in the pursuit of approval, protocols have become overly sanitised, stripped of nuance, overly cautious, and disconnected from real-world therapeutic practice.
Supporters counter that without this structure, the field risks credibility, safety, and legal viability.
Both sides are right.
And that is exactly the problem.
Australia’s Real-World Experiment
While the United States wrestles with regulatory gridlock, Australia has moved ahead.
In 2023, the Therapeutic Goods Administration rescheduled MDMA and psilocybin for limited therapeutic use under authorised prescribers.
On paper, this represents one of the most progressive regulatory shifts globally.
In practice, it has created a live experiment in protocol divergence.
Authorised prescribers are operating without a single, unified model. Some lean heavily on clinical trial frameworks. Others adapt protocols based on patient needs. Some incorporate elements of somatic therapy, trauma-informed care, or even spiritual frameworks.
There is no universal standard.
This has led to a quiet but important question circulating among clinicians:
Are we witnessing innovation or inconsistency?
The answer depends entirely on perspective.
For regulators, variability introduces risk. For therapists, it reflects reality.
Australia has become a microcosm of the Protocol Wars where competing approaches are not theoretical, but actively being tested in real time.
The RECAP / RE-SPCT Debate: Can You Standardise “Set and Setting”?
If there is one concept that defines psychedelic therapy, it is “set and setting.”
Mindset and environment are not secondary factors. They are central to the therapeutic outcome.
Yet efforts are now underway to standardise even these variables through emerging frameworks such as RECAP and the RE-SPCT guidelines.
These initiatives aim to improve trial consistency by formalising elements like:
- Therapist interaction styles
- Environmental design
- Preparation protocols
- Integration processes
The intention is clear: make psychedelic therapy more measurable, reproducible, and scalable.
But critics argue that this risks reducing deeply human experiences into checklists.
Can empathy be standardised?
Can trust be protocolised?
Can a therapeutic relationship be reduced to a repeatable model?
These are not philosophical questions. They are operational ones, with direct implications for how therapy is delivered—and who is allowed to deliver it.
The Therapist Bottleneck
While protocols dominate regulatory discussions, another constraint is emerging as equally critical: the therapist pipeline.
Psychedelic assisted therapy is not just about the medicine. It is about the container in which it is delivered.
And right now, that container is in short supply.
Training programs are expanding rapidly, but they are fragmented, expensive, and often inconsistent in quality. Some are affiliated with clinical research organisations. Others are independent. A few draw from indigenous or spiritual traditions.
There is no universally recognised credential.
This has created what many are calling “credential inflation” a landscape where practitioners accumulate multiple certifications, not necessarily because they improve outcomes, but because they signal legitimacy in an uncertain market.
At the same time, experienced underground facilitators, many with decades of practical knowledge remain excluded from formal systems.
The result is a paradox:
The people most qualified by experience are often the least recognised by regulation.
And the people most recognised by regulation are not always the most experienced.
This disconnect is becoming one of the defining tensions in the industry.
Indigenous Knowledge vs Clinical Ownership
Perhaps the most sensitive dimension of the Protocol Wars lies in the relationship between modern psychedelic therapy and traditional practices.
Long before clinical trials, indigenous communities across the Amazon, Mesoamerica, and beyond have developed sophisticated frameworks for working with psychoactive substances.
These are not protocols in the clinical sense. They are cultural systems deeply embedded in ritual, cosmology, and community.
As Western medicine begins to formalise psychedelic therapy, questions of ownership and legitimacy are becoming unavoidable.
Who has the right to define these practices?
Can ancient traditions be translated into clinical protocols without losing their essence?
And perhaps most controversially:
Is the current system extracting knowledge without adequately recognising its origins?
There are no easy answers here. But ignoring the tension is no longer an option.
The Scalability Problem
If regulation defines the structure of psychedelic therapy, scalability defines its commercial reality.
Investors are not funding boutique, one-patient-at-a-time experiences. They are funding clinics, networks, and platforms that can operate at scale.
But psychedelic therapy resists scale.
It is time intensive. It requires highly trained facilitators. It depends on trust, relationship, and presence factors that do not easily translate into high throughput models.
This creates a fundamental tension:
The deeper the therapy, the harder it is to scale. The more scalable it becomes, the more it risks losing depth.
Companies are already experimenting with solutions:
- Shorter session formats
- Group therapy models
- Digital integration tools
- AI-assisted preparation and integration
Each offers potential efficiency gains. Each also introduces new questions about quality and safety.
The Protocol Wars are not just about clinical frameworks. They are about business models.
Underground vs Above Ground
While regulators and companies debate protocols, a parallel ecosystem continues to operate largely outside formal systems.
Underground practitioners, often dismissed, sometimes romanticised remain a significant force in the psychedelic landscape.
They operate without regulatory approval, but often with deep experiential knowledge. Their approaches are typically adaptive, intuitive, and highly personalised.
For some patients, these practitioners offer something that clinical settings cannot: flexibility, authenticity, and accessibility.
For regulators, they represent risk.
For the industry, they represent both competition and an uncomfortable truth:
Not all effective psychedelic therapy fits within approved frameworks.
As legal access expands, the relationship between underground and above ground systems will become increasingly important.
Will one replace the other?
Or will they continue to coexist in tension?
Who Wins the Protocol Wars?
There is a temptation to frame this as a battle with a clear winner.
Pharma versus therapists. Regulation versus tradition. Scale versus depth.
But the reality is more complex.
The future of psychedelic therapy is unlikely to be defined by a single model. Instead, it will be shaped by a dynamic interplay between competing approaches.
What is clear, however, is this:
Whoever defines the dominant protocols will control the flow of capital, the structure of training, and the delivery of care.
Protocols determine:
- Who is qualified to practice
- What treatments are approved
- How clinics operate
- Where investment flows
In other words, protocols are not just clinical tools. They are instruments of power.
The Next Phase
The Protocol Wars are still in their early stages.
Over the next five years, several key developments will shape their trajectory:
Regulatory evolution will determine how flexible or rigid approved frameworks become. Training standardisation may create clearer pathways or further entrench gatekeeping. Clinical data will influence which models gain legitimacy. Market forces will push toward scalability, whether or not the therapy supports it.
And perhaps most importantly:
Patients themselves will shape the outcome.
Because ultimately, the most effective models—whether clinical, adaptive, or traditional—will be the ones that deliver real, measurable healing.
Everything else is noise.
Final Thought
Psychedelic therapy is often described as a revolution in mental health.
But revolutions are not just about new tools. They are about who gets to define how those tools are used.
The Protocol Wars are not a side story.
They are the story.
